J Gynecol Oncol.
2024 May;35(3):e94. 10.3802/jgo.2024.35.e94.
Enrichment for the POLE mutated against p53 wild subtype using clinicopathologic factors and cyclin B1 immunohistochemistry in endometrial cancer
- Parulekar M
1,2 - Kim H3
- Kim K1,4
- Ala A5
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea
- 2Department of Obstetrics and Gynecology, Galaxy Care Institute, Pune, India
- 3Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea
- 4Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
- 5Galilee Medical Center, Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel
- KMID: 2564910
- DOI: http://doi.org/10.3802/jgo.2024.35.e94
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinicopathologic and protein markers distinguishing the “polymerase epsilon exonuclease” from the “copy number low” subtype of endometrial cancer
- Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia
- Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer
- Overexpressions of Cyclin B1, cdc2, p16 and p53 in Human Breast Cancer: The Clinicopathologic Correlations and Prognostic Implications
- Prognostic Implications of Cyclin B1, p34cdc2, p27(Kip1) and p53 Expression in Gastric Cancer
